✦ LIBER ✦

FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy

✍ Scribed by William C Lavely; Dominique Delbeke; John P Greer; David S Morgan; Daniel W Byrne; Ronald R Price; Dennis E Hallahan

Book ID: 108435211
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 210 KB
Volume: 57
Category: Article
ISSN: 0360-3016
DOI: 10.1016/s0360-3016(03)00599-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Partial remission of a newly diagnosed d

Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP

✍ G. FELDMANN; J. NATTERMANN; T. GERHARDT; C. P. NÄHLE; U. SPENGLER; R. WOITAS 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

Combination of cyclophosphamide, vincris

Combination of cyclophosphamide, vincristine, and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with non-Hodgkin's lymphomas

✍ Gorin, N. C. ;David, R. ;Stachowiak, J. ;Najman, A. ;Duhamel, G. 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 548 KB

## Abstract Sixty patients with non‐Hodgkin's lymphomas were treated with a cyclophosphamide, vincristine, and prednisone (CVP) induction regimen, either alone (stage IV) or in combination with radiotherapy (stages I, II, III). The response rates for lymphocytic and histocytic lymphomas were 82 an

Role of whole-body [18F] fluorodeoxygluc

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma

✍ E. Pelosi; P. Pregno; D. Penna; D. Deandreis; A. Chiappella; G. Limerutti; U. Vi 📂 Article 📅 2008 🏛 Springer 🌐 Italian ⚖ 557 KB

Prolonged follow-up after initial therap

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma : Results of Cancer and Leukemia Group B Study 9153

✍ Kristie A. Blum; Jeffrey L. Johnson; Donna Niedzwiecki; Lawrence D. Piro; Alan S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 3 views

Etoposide, ifosfamide and methotrexate c

Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-hodgkin's lymphoma after failure of the LNH 84 regimen

✍ R. Herbrecht; S. Ortiz; J. C. Damonte; K. L. Liu; F. Maloisel; P. Dufour; J. P. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 353 KB

We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 8

Increased risk of myelotoxicity in elder

Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma : The case for routine prophylaxis with colony-stimulating factor beginning in the first cycle of chemotherapy

✍ Lodovico Balducci; Lazzaro Repetto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Neutropenia is the major dose‐limiting toxicity of myelosuppressive chemotherapy in patients with cancer. Because of the high incidence of neutropenic complications and death in the early cycles of chemotherapy and the potential for improved outcomes, prophylaxis with colony‐stimulating factor begin